Danaher Corporation (DHR)vsEquinor ASA ADR (EQNR)
DHR
Danaher Corporation
$187.15
-1.55%
HEALTHCARE · Cap: $134.43B
EQNR
Equinor ASA ADR
$40.46
+1.28%
ENERGY · Cap: $103.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinor ASA ADR generates 331% more annual revenue ($105.98B vs $24.57B). DHR leads profitability with a 14.7% profit margin vs 4.8%. DHR appears more attractively valued with a PEG of 1.23. DHR earns a higher WallStSmart Score of 60/100 (C).
DHR
Buy60
out of 100
Grade: C
EQNR
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.6%
Fair Value
$135.07
Current Price
$187.15
$52.08 premium
Margin of Safety
-116.7%
Fair Value
$13.19
Current Price
$40.46
$27.27 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.2%
Generating 1.7B in free cash flow
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 21.4%
Areas to Watch
Premium valuation, high expectations priced in
4.6% revenue growth
ROE of 7.0% — below average capital efficiency
4.8% margin — thin
Weak financial health signals
Expensive relative to growth rate
Revenue declined 5.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bull Case : EQNR
The strongest argument for EQNR centers on Market Cap, Price/Book, Operating Margin.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : EQNR
The primary concerns for EQNR are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
DHR carries more volatility with a beta of 0.96 — expect wider price swings.
DHR is growing revenue faster at 4.6% — sustainability is the question.
DHR generates stronger free cash flow (1.7B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (60/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Equinor ASA ADR
ENERGY · OIL & GAS INTEGRATED · USA
Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?